Magnesium supplementation for better control of Type 2 Diabetes
The Effect of Oral Magnesium Supplementation on The Control and Outcomes of Type II Diabetes Mellitus Guided by Serum Ionized Magnesium Level: A Double-Blind Randomized Control Trial
This study is testing if taking magnesium supplements can help people with Type 2 Diabetes who have low magnesium levels manage their diabetes better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sultan Qaboos University Academic / other |
| Locations | 1 site (Muscat) |
| Trial ID | NCT05774015 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of oral magnesium supplementation on patients with Type 2 Diabetes Mellitus (T2DM) who have low serum ionized magnesium levels. The hypothesis is that magnesium supplementation, guided by serum ionized magnesium levels, may improve diabetes control and overall disease outcomes. Unlike previous trials that focused on healthy individuals, this study specifically targets T2DM patients and aims to establish a correlation between magnesium levels and diabetes management. Participants will receive magnesium oxide tablets at a dosage of 500 mg.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with Type 2 Diabetes who have an HbA1c level of 7% or higher and are being treated with oral hypoglycemic agents.
Not a fit: Patients with an HbA1c below 7%, those with end-stage renal disease, or those on certain contraindicated medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved diabetes management and better health outcomes for patients with Type 2 Diabetes.
How similar studies have performed: While previous studies have explored magnesium supplementation, this specific approach targeting T2DM patients based on serum ionized magnesium levels is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults (≥18 years old). * Treated with oral hypoglycemic agents (OHA) ± insulin regimen. * Had HbA1c ≥ 7% in the last 3 months Exclusion Criteria: * HbA1c of \< 7%. * Fully dependent patients as per clinical frailty score * End stage renal disease (creatinine clearances (CrCl) at \< 10ml/min) * With neuromuscular disease * With active solid or hematological malignancies. * With cognitive disorders. * With the following regular medications (baloxavir marboxil, calcium/sodium polystyrene sulfate, raltegravir, or unithiol) due to X category drug-drug interaction (contraindicated combinations) when given concurrently Mg oxide
Where this trial is running
Muscat
- Mohammed AlZa'abi — Muscat, Oman (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.